Prime Medicine (PRME) Competitors $6.18 +0.73 (+13.39%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock PRME vs. XENE, GMTX, SRRK, RARE, AMRX, IMVT, CNTA, TARS, APLS, and MORShould you be buying Prime Medicine stock or one of its competitors? The main competitors of Prime Medicine include Xenon Pharmaceuticals (XENE), Gemini Therapeutics (GMTX), Scholar Rock (SRRK), Ultragenyx Pharmaceutical (RARE), AMNEAL PHARMACEUTICALS (AMRX), Immunovant (IMVT), Centessa Pharmaceuticals (CNTA), Tarsus Pharmaceuticals (TARS), Apellis Pharmaceuticals (APLS), and MorphoSys (MOR). These companies are all part of the "pharmaceutical products" industry. Prime Medicine vs. Its Competitors Xenon Pharmaceuticals Gemini Therapeutics Scholar Rock Ultragenyx Pharmaceutical AMNEAL PHARMACEUTICALS Immunovant Centessa Pharmaceuticals Tarsus Pharmaceuticals Apellis Pharmaceuticals MorphoSys Prime Medicine (NASDAQ:PRME) and Xenon Pharmaceuticals (NASDAQ:XENE) are both pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings. Do analysts recommend PRME or XENE? Xenon Pharmaceuticals has a consensus price target of $53.67, suggesting a potential upside of 23.54%. Given Xenon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Xenon Pharmaceuticals is more favorable than Prime Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prime Medicine 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Xenon Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.92 Does the media prefer PRME or XENE? In the previous week, Xenon Pharmaceuticals had 12 more articles in the media than Prime Medicine. MarketBeat recorded 13 mentions for Xenon Pharmaceuticals and 1 mentions for Prime Medicine. Xenon Pharmaceuticals' average media sentiment score of 0.65 beat Prime Medicine's score of 0.00 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xenon Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of PRME or XENE? 70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. 22.7% of Prime Medicine shares are owned by company insiders. Comparatively, 4.1% of Xenon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is PRME or XENE more profitable? Xenon Pharmaceuticals has a net margin of 0.00% compared to Prime Medicine's net margin of -4,016.83%. Xenon Pharmaceuticals' return on equity of -38.50% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Prime Medicine-4,016.83% -156.16% -64.41% Xenon Pharmaceuticals N/A -38.50%-36.47% Which has more volatility & risk, PRME or XENE? Prime Medicine has a beta of 2.65, indicating that its stock price is 165% more volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. Which has preferable earnings & valuation, PRME or XENE? Prime Medicine has higher earnings, but lower revenue than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrime Medicine$2.98M279.07-$195.88M-$1.56-3.96Xenon Pharmaceuticals$9.43M355.21-$234.33M-$3.55-12.24 SummaryXenon Pharmaceuticals beats Prime Medicine on 12 of the 17 factors compared between the two stocks. Get Prime Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRME vs. The Competition Export to ExcelMetricPrime MedicineBiological Products, Except Diagnostic Substances IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$733.43M$270.08M$2.52B$10.56BDividend YieldN/AN/A2.50%4.84%P/E Ratio-3.96N/A21.8427.34Price / Sales279.07371.70115.98132.57Price / CashN/AN/A44.3430.35Price / Book5.283.2335.226.69Net Income-$195.88M-$111.70M$6.87M$276.46M7 Day Performance9.38%-3.57%0.82%0.97%1 Month Performance26.38%7.31%0.63%3.95%1 Year PerformanceN/AN/A126.44%36.40% Prime Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRMEPrime Medicine0.2479 of 5 stars$6.18+13.4%N/AN/A$733.43M$2.98M-3.96N/AGap UpXENEXenon Pharmaceuticals2.7582 of 5 stars$40.57+1.5%$53.67+32.3%-7.2%$3.13B$9.43M-11.43210GMTXGemini TherapeuticsN/A$71.96+2.9%N/A+77.9%$3.12BN/A-71.9630Gap UpHigh Trading VolumeSRRKScholar Rock4.4368 of 5 stars$31.90-6.9%$48.60+52.4%-8.5%$3.07B$33.19M-10.96140Analyst ForecastHigh Trading VolumeRAREUltragenyx Pharmaceutical4.4053 of 5 stars$31.69-1.0%$81.50+157.2%-42.0%$3.05B$560.23M-5.731,294Analyst ForecastAMRXAMNEAL PHARMACEUTICALS2.1194 of 5 stars$9.72-0.3%$12.00+23.5%+15.6%$3.05B$2.79B972.978,100IMVTImmunovant2.3746 of 5 stars$17.49+0.8%$28.78+64.5%-40.6%$3.05BN/A-6.14120Gap DownCNTACentessa Pharmaceuticals3.5955 of 5 stars$22.41-0.3%$32.38+44.5%+43.4%$3.00B$15M-12.52200Analyst DowngradeTARSTarsus Pharmaceuticals1.3214 of 5 stars$69.83-0.7%$66.67-4.5%+99.2%$2.95B$182.95M-29.9750Analyst ForecastAPLSApellis Pharmaceuticals4.2851 of 5 stars$23.15-4.1%$33.29+43.8%-12.4%$2.92B$781.37M-12.72770Insider TradeMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730 Related Companies and Tools Related Companies Xenon Pharmaceuticals Competitors Gemini Therapeutics Competitors Scholar Rock Competitors Ultragenyx Pharmaceutical Competitors AMNEAL PHARMACEUTICALS Competitors Immunovant Competitors Centessa Pharmaceuticals Competitors Tarsus Pharmaceuticals Competitors Apellis Pharmaceuticals Competitors MorphoSys Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRME) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredTrump Issues Surprise Emergency OrderIs This Stock the 'Next Nvidia'? Billionaire Warren Buffett has been loading up on millions of shares of th...Altimetry | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCould this strange machine change society forever?A mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prime Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
